Company Profile
Pulmatrix Stock Price, News & Catalysts
- Ticker:
- PULM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.56 USD (+1.30%)
Close
Last updated: August 17, 2026
4.82M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, PULM closed up 1.30% at $1.56. No new same-company headline was identified in the current news window.
Company overview
Inhaled Drug-Delivery Company
Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology. The company is seeking partners or other monetization routes for its legacy clinical assets while pursuing a merger with Eos SENOLYTIX.
iSPERSE Technology
iSPERSE creates small, dense, dispersible particles intended to improve pulmonary drug delivery compared with conventional dry powders.
PUR1900
PUR1900 is an inhaled formulation of itraconazole for fungal lung disease. Partner Cipla controls continued development in India.
PUR3100 and PUR1800
PUR3100 is a Phase 2-ready inhaled dihydroergotamine program for acute migraine, while PUR1800 is an inhaled kinase inhibitor previously studied in chronic obstructive pulmonary disease.
Future catalysts
- Initiation of the Cipla-led Phase 3 study of PUR1900 in India in 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pulmatrix (PULM)?
Pulmatrix (PULM) most recently closed at 1.56 USD, a +1.30% move versus the previous session.
What is the market cap of Pulmatrix (PULM)?
Pulmatrix currently has a market capitalization of 4.82M USD on BioPharmSignal.
What does Pulmatrix do?
Inhaled Drug-Delivery Company Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology. The company is seeking partners or other monetization routes for its legacy clinical assets while pursuing a merger with Eos SENOLYTIX. iSPERSE Technology iSPERSE creates small, dense, dispersible particles intended to improve pulmonary...
On which exchange is PULM stock listed?
Pulmatrix (PULM) is associated with NASDAQ, United States, Biopharma.
What is Inhaled?
Inhaled Drug-Delivery Company Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology.
Which conditions is Pulmatrix targeting with Inhaled?
Inhaled Drug-Delivery Company Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology. The company is seeking partners or other monetization routes for its legacy clinical assets while pursuing a merger with Eos SENOLYTIX. iSPERSE Technology iSPERSE creates small, dense, dispersible particles intended to improve pulmonary...
How does Pulmatrix describe recent progress with Inhaled?
Initiation of the Cipla-led Phase 3 study of PUR1900 in India in 2026.
What is Drug-Delivery?
Inhaled Drug-Delivery Company Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology.